# Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19

> **NCT04486521** · — · UNKNOWN · sponsor: **King Faisal Specialist Hospital & Research Center** · enrollment: 860 (estimated)

## Conditions studied

- Critical Illness
- Corona Virus Infection
- Cytokine Release Syndrome

## Interventions

- **DRUG:** Interleukin 6 (IL6) Antagonist
- **DRUG:** Interleukin 6 (IL6) Antagonist and corticosteroids
- **DRUG:** corticosteroid alone

## Key facts

- **NCT ID:** NCT04486521
- **Lead sponsor:** King Faisal Specialist Hospital & Research Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-22
- **Primary completion:** 2021-07-22
- **Final completion:** 2021-07-22
- **Target enrollment:** 860 (ESTIMATED)
- **Last updated:** 2021-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486521, "Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04486521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*